Updates are available Correction dated 2021-11-03
Click to view Correction: https://doi.org/10.1186/s12916-021-02141-y
-
Authors
Haverfield, Eden V. https://orcid.org/0000-0002-2126-0982
Esplin, Edward D.
Aguilar, Sienna J.
Hatchell, Kathryn E.
Ormond, Kelly E.
Hanson-Kahn, Andrea
Atwal, Paldeep S.
Macklin-Mantia, Sarah
Hines, Stephanie
Sak, Caron W.-M.
Tucker, Steven
Bleyl, Steven B.
Hulick, Peter J.
Gordon, Ora K.
Velsher, Lea
Gu, Jessica Y. J.
Weissman, Scott M.
Kruisselbrink, Teresa
Abel, Christopher
Kettles, Michele
Slavotinek, Anne
Mendelsohn, Bryce A.
Green, Robert C.
Aradhya, Swaroop
Nussbaum, Robert L.
- License Information
-
More Information
Article History
Received: 19 January 2021
Accepted: 29 April 2021
First Online: 18 August 2021
Change Date: 3 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12916-021-02141-y
Declarations
:
: All patients provided informed consent (either written or verbal) before genetic screening tests were ordered. Relevant clinically reported variants and de-identified clinical information were collected for analyses with institutional review board approval (Western IRB, #20160282). The need for additional consent was waived.
: Not applicable
: EVH, EDE, SJA, KEH, SA, and RLN are employees and stockholders of Invitae. SBB is an employee and stockholder of Genome Medical. LV receives a stipend from MedCan for her contributions as a medical advisor. RCG is a co-founder of Genome Medical and receives compensation for advising AIA, Grail, OptumLabs, Verily, and Wamburg. KEO, AH-K, PSA, SM-M, SH, CW-MS, ST, PJH, OKG, JYJG, SMW, TK, CA, MK, AS, and BAM declare no conflicts of interest.
